Skip to search formSkip to main contentSkip to account menu

ATN-161

A small peptide antagonist of integrin alpha5beta1 with potential antineoplastic activity. ATN-161 selectively binds to and blocks the receptor for… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
INTEGRIN α5β1 AS A NOVEL TARGET WITH THE SMALL PEPTIDE, ATN-161, IN THE TREATMENT OF ISCHEMIC STROKE
OF DISSERTATION INTEGRIN α5β1 AS A NOVEL TARGET WITH THE SMALL PEPTIDE, ATN-161, IN THE TREATMENT OF ISCHEMIC STROKE Stroke is… 
2018
2018
Abstract TMP28: Inhibition of Integrin α 5 β 1 With the Small Peptide Atn-161 Reduces Infarct Volume and Improves Functional Recovery Through Reduction of Blood-brain Barrier Permeability
Reperfusion-induced injury after recanalization is exacerbated by blood-brain barrier (BBB) dysfunction after ischemic stroke… 
2017
2017
First plasma and tissue pharmacokinetic study of the YSNSG cyclopeptide, a new integrin antagonist, using microdialysis
2015
2015
Synergistic anti-angiogenic effect of ATN-161 and anti-VEGF antibody in a rat model of wet age-related macular degeneration
2011
2011
Overstimulated NMDA receptor impairs brain development
2011
2011
Promotion of neurite outgrowth by an endogenous Nogo66 receptor antagonist LOTUS
2011
2011
The role of Notch-pathway in the monolayer formation of Bergmann glial cells
2011
2011
Prolyl hydroxylase (PHD) inhibitors prevent cortical neurite elongation by a mechanism dependent on RhoA/Rho-associated protein kinase (ROCK)
2011
2011
Dopaminergic innervation of striatal neurons through integrin α5β1
2004
2004
Regression of primary breast tumor and blockage of osteolytic skeletal metastasis by a non-RGD based integrin binding peptide (ATN-161) targeting α5β1 and αvβ3 in a xenograft model of breast cancer
Proc Amer Assoc Cancer Res, Volume 45, 2004 4001 Breast cancer is commonly associated with osteolytic skeletal metastasis… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)